Ninety Minutes Each Way: Weighing a Twice-Yearly Biologic Against a Six-Month Blind Spot
An adherence problem that a twice-yearly biologic would genuinely solve, in a patient whose one hospitalization last year is exactly the kind of event a six-month monitoring gap could miss early.
Renata S. works as a home-health aide across three rural counties, which means her actual schedule on any given week depends on which of her clients needs her and when — not something that lines up neatly with an eight-week injection slot ninety minutes from the nearest clinic that stocks her biologic. She has missed or delayed three of her last eleven benralizumab doses, not from any change of mind about the drug but because a client’s emergency or a canceled ride kept winning out. Fourteen months ago, in the middle of one of those gaps, she was hospitalized for four days with a severe exacerbation — the only hospitalization she has had since starting biologic therapy, and one her team has not stopped connecting to the missed doses on either side of it.
Depemokimab, approved in December 2025 as the first twice-yearly biologic in this class, is built for exactly the access problem she has: two doses a year instead of six, a schedule her actual working life could plausibly keep. Her blood eosinophil count of 380 cells/µL clears the SWIFT trial program's own enrollment threshold with room to spare, and the trial data itself is real — a 58% reduction in annualized exacerbations in one replicate study, 48% in the other. What the same data cannot answer is what happens if it does not work for her specifically: SWIFT was studied in patients starting fresh, not in someone already established on another biologic. The trial that did study that switch, NIMBLE, missed its non-inferiority margin — and its prespecified split by prior biologic put the excess almost entirely among patients coming off benralizumab, at roughly a 38% higher exacerbation rate, while those coming off mepolizumab did about as well as those who stayed put. Benralizumab is what Renata would be coming off. Her access problem argues one way and the only switch data that actually describes her argues the other, and the six-month dosing interval means an inadequate response would show up on nothing but her breathing for half a year.
Weighing convenience against how long a wrong answer could go unnoticed
Her actual, documented problem is not that benralizumab has stopped working — it is that an eight-week schedule collides with a job where her own hours are not hers to set. Two doses a year is not a convenience feature for her, it is a direct fix for the exact gap that led to her one hospitalization. Her eosinophil count of 380 clears SWIFT’s own enrollment bar comfortably, and that trial’s exacerbation reduction — 58% and 48% across its two replicate studies — is real, twice-confirmed evidence.
I do not disagree that her access problem is real and that depemokimab is built for exactly it. What I would weight more is that she already has one hospitalization on record, and a six-month interval is also six months before we would see a clear signal if this particular switch does not go as well as SWIFT’s treatment-naive population suggests it should. For most patients I would not raise this. For a patient with her specific history, I want to know how we are watching her in month two and month four, not just at the next injection.
Worth naming plainly: NIMBLE, the only trial that has actually tested switching an established patient onto depemokimab, did not meet its own non-inferiority margin — a rate ratio of 1.16 against a prespecified ceiling of 1.28. But the headline is not the part that matters most for Renata. NIMBLE’s prespecified analysis by prior biologic found the mepolizumab switchers came out comparable to those who stayed on treatment, while the excess sat almost entirely with the benralizumab switchers, at roughly a 38% higher exacerbation rate. She is on benralizumab. So she is not outside that trial’s population on the axis that drove its result — she is inside the half of it that did worse.
This is still not an argument against depemokimab — her access problem is real, and a dose she actually receives beats a better dose she misses. It is an argument that the interim check stops being ordinary prudence here and starts standing in for a subgroup result that ran against her.
Agreed: switch to depemokimab, with explicit phone check-ins at week eight and week sixteen added specifically to close the monitoring gap a six-month interval would otherwise leave — and sharpened, once NIMBLE’s prior-biologic split was on the table, from general prudence into cover for a subgroup result that ran against her.
Not fully agreed: the pulmonologist would have preferred an in-person visit at the midpoint rather than a phone check-in, given her hospitalization history; the allergist argued an in-person visit reintroduces the same access barrier the switch was meant to solve. The phone check-in was accepted as a compromise, not a consensus first choice.